We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche’s Actemra Missed All Key Endpoints When Paired with Remdesivir to Treat COVID-19
Roche’s Actemra Missed All Key Endpoints When Paired with Remdesivir to Treat COVID-19
Roche reported that its arthritis drug Actemra (tocilizumab), when paired with the antiviral remdesivir (Veklury) from Gilead Sciences, did not meet the endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.